Open AccessPrevention of Microalbuminuria in Patients With Type 2 Diabetes: What Do We Know?
Author(s) -
Ruilope Luis,
Izzo Joseph,
Haller Hermann,
Waeber Bernard,
Oparil Suzanne,
Weber Michael,
Bakris George,
Sowers James
Publication year - 2010
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1751-7176.2010.00289.x
Subject(s) - microalbuminuria , medicine , disease , kidney disease , diabetes mellitus , type 2 diabetes , intensive care medicine , population , blood pressure , etiology , intervention (counseling) , clinical trial , endocrinology , environmental health , psychiatry
J Clin Hypertens (Greenwich). 2010;12:422–430. © 2010 Wiley Periodicals, Inc. Cardiovascular and chronic kidney disease are epidemic throughout industrialized societies. Diabetes leads to premature cardiovascular disease and is regarded by many as the most common etiological factor for chronic kidney disease. Because most studies of blood‐pressure lowering agents in people with diabetes and hypertension have been conducted in individuals who already have some target organ damage, it is unclear whether earlier intervention could prevent or delay the onset of renal or systemic vascular disease. In early disease there is only a low possibility of observing cardiovascular or renal events; thus intervention trials in this population must rely on disease markers such as microalbuminuria. Accordingly, the authors review the evidence to support the use of microalbuminuria as a disease marker in diabetic patients based on its strong association with renal and cardiovascular events, and discuss recent trials that examine the impact of preventing or delaying the onset of microalbuminuria.